LoQus23 Therapeutics Ltd. has nominated, and is progressing, LQT-23, a drug candidate with the potential to slow or stop the progression of Huntington’s disease (HD).
Huntington’s disease is an autosomal dominant neurodegenerative disorder for which there is currently no approved disease modifying treatment. By targeting somatic expansion, LoQus23 is hoping to slow or even halt the onset and progression of Huntington’s disease.
DNA mismatch repair has been shown as a key driver of HD and other triplet repeat diseases. Convergent evidence from human genetics, post-mortem studies, and mechanistic research identifies MSH3/MutSβ as the most promising target of the DNA mismatch repair pathway. However, the protein is a highly challenging target for small molecule therapeutic intervention.
LoQus23 has established a platform of assays and multiple series of small molecule MutSβ inhibitors. LQT-23 represents an advancement in MutSβ modulation for the treatment of HD, employing a novel mechanism of action to inhibit this complex target. LQT-23 is the most advanced and potent allosteric small molecule inhibitor of MutSβ to date.
David Reynolds, chief executive officer of LoQus23 Therapeutics, said: “The nomination of LQT-23 as our development candidate is a significant moment for LoQus23 and reaffirms our strategy of advancing our pipeline of MSH3/MutSβ inhibitors to transform the lives of patients. I want to salute the dedication of our team which has worked tirelessly over many years to identify this candidate for such a difficult target, and we look forward to advancing it to IND/CTA filing later this year.”
Cyrus Mozayeni, chair of the board of directors of LoQus23, said: “MSH3/MutSβ is the most promising and best validated target for HD, but has been difficult to drug. The team has made exceptional progress since the financing in 2024, and the nomination of LQT-23 as our lead development candidate underscores our deep domain expertise, while positioning LoQus23 at the forefront of emerging therapies for the treatment of HD.”
Preclinical studies of LQT-23 have demonstrated potent and selective modulation of MSH3/MutSβ which leads to robust blockade of somatic expansion in HD cellular systems and animal models. Pre-clinical development will continue through 2026.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.